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Aim: Effective treatment of premature infants with bronchopulmonary dysplasia (BPD)
is lacking. We hypothesize that bone morphogenetic protein 9 (BMP9), a ligand of the
TGF-β family that binds to the activin receptor-like kinase 1 (ALK1)-BMP receptor type
2 (BMPR2) receptor complex, may be a novel therapeutic option for BPD. Therefore,
we investigated the cardiopulmonary effects of BMP9 in neonatal Wistar rats with
hyperoxia-induced BPD.
Methods: Directly after birth Wistar rat pups were exposed to 100% oxygen for 10
days. From day 2 rat pups received BMP9 (2.5 µg/kg, twice a day) or 0.9% NaCl by
subcutaneous injection. Beneficial effects of BMP9 on aberrant alveolar development,
lung inflammation and fibrosis, and right ventricular hypertrophy (RVH) were investigated
by morphometric analysis and cytokine production. In addition, differential mRNA
expression of BMP9 and its receptor complex: ALK1, BMPR2, and Endoglin, and of the
ALK1 downstream target transmembrane protein 100 (TMEM100) were studied during
the development of experimental BPD. Expression of the BMP9 receptor complex and
TMEM100 was studied in human endothelial and epithelial cell cultures and the effect of
BMP9 on inflammatory cytokine production and TMEM100 expression was studied in
endothelial cell cultures.
Results: ALK1, ALK2, BMPRII, TMEM100, and Endoglinwere differentially expressed in
experimental BPD, suggesting a role for BMP9-dependent signaling in the development
of (experimental) BPD. TMEM100 was expressed in the wall of blood vessels,
showing an elastin-like expression pattern in arterioles. Expression of TMEM100
mRNA and protein was decreased after exposure to hyperoxia. BMP9 treatment of
rat pups with hyperoxia-induced experimental BPD reduced alveolar enlargement,
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lung septal thickness and fibrosis, and prevented inflammation, but did not attenuate
vascular remodeling and RVH. The anti-inflammatory effect of BMP9 was confirmed in
vitro. Highest expression of ALK1, BMPR2, and TMEM100 was observed in human
endothelial cell cultures. Stimulation of human endothelial cell cultures with BMP9
reduced their pro-inflammatory cytokine response and induced TMEM100 expression
in pulmonary arterial endothelial cells.
Conclusion: BMP9 protects against neonatal hyperoxia-induced BPD by improving
aberrant alveolar development, inflammation and fibrosis, demonstrating its therapeutic
potential for premature infants with severe BPD.
Keywords: bronchopulmonary dysplasia, lung fibrosis, activin receptor-like kinase 1, right ventricular hypertrophy,
transmembrane protein 100
INTRODUCTION
Experimental and clinical evidence is accumulating that
premature birth can have a major impact on neonatal lung
development and morbidity that may persist into adulthood
(Baraldi and Filippone, 2007). Advanced neonatal intensive
care with non-invasive ventilation and surfactant therapy has
sharply increased survival of even the youngest premature
infants at the expense of increased morbidity, including brain
damage due to cerebral bleedings and hypoxia, gastro-intestinal
complications, retinopathy, chronic lung disease, and pulmonary
hypertension-induced right ventricular hypertrophy (RVH).
The immature lung is highly susceptible to injury caused by
mechanical ventilation and supplemental oxygen administration
during treatment of respiratory distress syndrome (RDS) and
this may progress toward chronic lung disease, known as
bronchopulmonary dysplasia (BPD). BPD is the most common
complication in survivors of very premature birth, born at <30
weeks of gestation (Baraldi and Filippone, 2007). The hallmark of
BPD is lung emphysema due to an arrest in alveolar and vascular
development, and lung injury. BPD leads to simplification
of the alveolar structures and impaired lung function, and is
complicated by inflammation and oxidative stress-induced
alveolar destruction. Survivors of BPD are severely affected later
in life as they end up with persistent impaired lung function and
are at high risk of developing respiratory infections with frequent
rehospitalizations, asthma, cardiac failure due to pulmonary
arterial hypertension (PAH), and possibly chronic obstructive
pulmonary disease (COPD) (Baraldi and Filippone, 2007; Wong
et al., 2008; Steinhorn, 2010).
Clinical treatment for BPD is mainly supportive as currently
available treatment options are limited to caffeine administration
to stimulate respiratory drive in the brain, glucocorticoids for
weaning from the ventilator and vitamin A administration.
However, effective treatment options to prevent or stimulate
repair of the injured lung of BPD patients is still lacking.
Unfortunately, clinical trials of inhaled nitric oxide (iNO) as
treatment option for BPD failed to improve lung function and
the translation to the clinic of sildenafil to treat BPD is not
an option anymore because the food and drug agency (FDA)
issued a safety warning against the use of sildenafil in children
after reports of increased mortality rates in children treated
for pulmonary hypertension at high concentrations of sildenafil
(Kinsella et al., 2014; Perez and Laughon, 2015). Therefore, novel
therapeutic drugs need to be identified for the treatment of BPD
using suitable animal models, such as new born rodents (Koppel
et al., 1994; de Visser et al., 2009, 2010, 2012; Alapati et al.,
2011; Hilgendorff et al., 2014; Chen et al., 2016). Newborn rats
and mice have immature lungs and develop persistent alveolar
simplification, chronic lung inflammation, fibrosis, PAH, and
RVH after several days of exposure to hyperoxia, mimicking
severe BPD (de Visser et al., 2010, 2012; Madurga et al., 2013;
Berger and Bhandari, 2014; Hilgendorff et al., 2014; O’Reilly
and Thebaud, 2014). Clinical and experimental evidence is
accumulating that excessive transforming growth factor-β (TGF-
β)-signaling in premature infants and rodents contributes to
the development and severity of lung injury and (experimental)
BPD: (1) Increased expression of TGF-β has been observed
in the lungs of children with BPD and increased expression
of TGF-β and its receptors was found in neonatal and adult
animals with lung disease (Lecart et al., 2000; Vicencio et al.,
2002; Alejandre-Alcazar et al., 2007, 2008; Morty et al., 2009;
Tatler and Jenkins, 2012), (2) Overexpression of TGF-β in
neonatal mice and rats resulted in experimental BPD (Gauldie
et al., 2003; Vicencio et al., 2004), and (3) TGF-β neutralizing
antibodies and pharmacological inhibition of TGF-β reduced
lung injury and improved alveolarization inmice with hyperoxia-
induced neonatal lung injury (Nakanishi et al., 2007; Sakurai
et al., 2011). Interventions in the signaling pathways initiated
by the TGF-β family of proteins, including TGF-β and bone
morphogenetic proteins (BMPs), may therefore have important
therapeutic potential for BPD (Morty et al., 2009). Although,
BMP9 protects against PAH in adult mice and rats (Long et al.,
2015) and BMP type II receptor (BMPRII) dysfunction enhances
lung inflammation (Kim et al., 2013; Talati et al., 2014; Soon et al.,
2015), the role of this TGF-β family member in neonatal chronic
lung disease is unknown. BMP9 exerts its multiple biological
effects after binding to a heterotetrameric transmembrane
receptor complex that consists of activin receptor-like kinase 1
(ALK1) or ALK2 with ALK1 being the high affinity receptor for
BMP9, and BMPRII, which may be enhanced by the accessory
receptor endoglin (Upton et al., 2009; Pardali and Ten Dijke,
2012). Activated ALK1 (or ALK2) phosphorylates Smad1/5/8,
which form complexes with Smad4 that translocate to the
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nucleus to regulate gene expression by interacting with other
transcription factors. Alternatively, ALK1/BMPRII signalingmay
be mediated via non-Smad signaling, e.g., by activating MAP
kinases (Pardali and Ten Dijke, 2012). Indirect evidence for
a role of BMP9-ALK1-dependent signaling comes from our
previous studies on identifying novel genes in the pathogenesis
of BPD using a DNA array experimental setup (Wagenaar
et al., 2004) in which we identified the unknown expressed
sequence tags with accession numbers AI168935 and AI058357,
as being transmembrane protein 100 (TMEM100), a downstream
target gene of ALK1 (Somekawa et al., 2012), with a very high
differential expression in rat pups with experimental BPD.
The effect of BMP9 on the clinical progression of BPD is
unknown. To advance our knowledge on BMP9 signaling in
neonatal cardiopulmonary disease, we studied (1) the spatial
and/or temporal expression of BMP9, its receptor complex and
its downstream target transmembrane protein 100 (TMEM100;
Somekawa et al., 2012) in neonatal rat lung, (2) the beneficial
effects of BMP9 in neonatal rats with hyperoxia-induced BPD
and investigated lung alveolarization, inflammation, fibrosis,
vascular remodeling, and RVH as described previously (de Visser
et al., 2010; Chen et al., 2016), and (3) BMP9 signaling in cultured
human epithelial and endothelial cells and the anti-inflammatory
potential of BMP9 in cultured human endothelial cells.
MATERIALS AND METHODS
Animals
All animal experiments were performed in accordance with the
Institute for Laboratory Animal Research Guide for the Care and
Use of Laboratory Animals and were approved by the Animal
Ethical Committee (Leiden University Medical Center, Leiden,
the Netherlands). Six months old adult Wistar rats (N = 6) were
anesthetized with an intraperitoneal injection of ketamine (50
mg/kg) and xylazine (50 mg/kg) and exsanguinated by cutting
the abdominal blood vessels. Organs were stored at −80◦C until
isolation of RNA for real time RT-PCR. For each intervention
experiment, newborn Wistar rat pups from 3 to 5 litters were
pooled and assigned ad random to 4 experimental groups: an
oxygen-NaCl group (N = 6), an oxygen-BMP9 group (N =
6), and two room air (RA)-exposed control groups (N = 6
each). All oxygen-exposed pups were housed together in Plexiglas
chambers and were exposed continuously to 100% oxygen for
10 days. Pups were fed by foster dams and received twice a
day subcutaneous injections with either 2.5 µg/kg of BMP9
dissolved in 100 µl 0.9% NaCl or solvent only from day 2 after
birth until day 10. Recombinant BMP9 consisting of the human
growth factor domain and the mouse prodomain was obtained
from Pfizer, as previously described (Long et al., 2015). To avoid
oxygen toxicity foster dams were rotated daily: 24 h in hyperoxia
and 48 h in RA. Once a day evidence of disease, mortality,
body weight, and oxygen concentration, were recorded. On day
10 rat pups were exsanguinated under ketamine and xylazine
anesthesia. Hereafter, lungs and hearts were collected. Lungs
were fixed under constant pressure (27 cm H2O) in formalin
for histology studies or snap-frozen in liquid nitrogen for fibrin
deposition assay, cytokine assays and RT-qPCR as described
previously (de Visser et al., 2009, 2010). Separate experiments
were performed to obtain: (1) formalin fixed lung and heart
tissue for histology (N = 8); (2) lung homogenates for fibrin
deposition (N = 8); (3) broncho-alveolar lavage fluid (BALF) for
protein measurements (N = 10); (4) lung tissue from neonates
with experimental BPD and RA controls on days 1, 3, 6, and 10
after birth for RT-PCR (N = 6–8). For all parameters, at least two
independent experiments were performed.
Histology
Lung and heart tissue was fixed in formalin and embedded
in paraffin. Four micrometers thick paraffin-embedded
tissue sections were deparaffinized and subsequently stained
with hematoxylin and eosin (HE). In addition, lung tissue
sections were immune-stained with anti-ED-1 (monocytes and
macrophages; 1:5), anti-myeloperoxidase (MPO, RB-373-A1,
Thermo Fisher Scientific, Fremont, CA, USA; diluted 1:1,500),
anti-α smooth muscle actin (αSMA, A2547, Sigma-Aldrich, St.
Louis, MO, USA; diluted 1:20,000), anti-von Willebrand factor
(vWF, A0082, Dako Cytomation, Glostrup, Denmark; diluted
1:4,000), anti-collagen III (COL3A1, ab7778; Abcam; diluted
1:3,000), anti-pSMAD1 [diluted 1:2,000; this antibody cross-
reacts with pSMAD5 and pSMAD8, which also act downstream
of BMP type I receptors (Persson et al., 1998; Rosendahl et al.,
2002)], anti-pSMAD2 (diluted 1:2,000), (Persson et al., 1998;
Rosendahl et al., 2001) and anti-transmembrane protein 100
(TMEM100, GTX83508; Gene Tex, Irvine, CA, USA; diluted
1:400), using the chromogenic substrate NovaRed or NovaRed
and Vector SG Substrate on αSMA and vWF double stained
sections, respectively (Vector, Burlingame, CA, USA), and
counterstained briefly with hematoxylin using standard methods
(de Visser et al., 2009, 2010). Furthermore, elastin was visualized
on Hart’s stained lung sections (Simon et al., 2010). We used a
Weibel type II ocular micrometer (Olympus, Zoeterwoude, The
Netherlands) for morphometric analysis of the lung, (Wagenaar
et al., 2004). Different (immuno)histochemically stained lung
sections were used for each quantification. However, alveolar
crests and pulmonary arteriolar wall thickness were determined
on the same αSMA stained section. To exclude potential effects
of heterogeneous alveolar development we investigated alveolar
enlargement in experimental BPD in two different ways by
studying mean linear intercept (MLI) and the number of alveolar
crests. The MLI, determined on hematoxylin and eosin stained
lung sections, was assessed in 10 non-overlapping fields at a 200x
magnification for each animal (Dunnill, 1962; de Visser et al.,
2010). The quantification of alveolar crests is an indicator of
the number of alveoli (Yi et al., 2004). The number of alveolar
crests (Yi et al., 2004) was determined on αSMA-stained lung
sections at a 400x magnification in 10 non-overlapping fields
for each animal and were normalized to tissue and field. The
number of MPO-positive neutrophilic granulocytes or ED-1
positive monocytes and macrophages was determined in the
alveolar compartment and normalized to field and expressed as
cells per mm2. Twenty fields in one section were studied at a
400x magnification for each experimental rat. HE-stained lung
sections were used at a 400x magnification for alveolar septal
thickness measurements by averaging 100 measurements per
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10 representative fields. The number of vessels per field were
counted at a 200x magnification in vWF-stained lung sections to
determine capillary density. At least 10 representative fields per
experimental animal were investigated. Results were expressed
as relative number of vessels per mm2. Arteriolar wall thickness
was assessed twice in elastin- or αSMA-stained lung sections
at a 1,000x magnification by averaging at least 10 vessels with
a diameter of <30 µm per rat for each of the two different
staining methods. Medial wall thickness was calculated from the
formula “percent wall thickness = 2∗wall·thickness
external·diameter
∗100” (Koppel
et al., 1994). Muscularization of small arterioles (<50 µm) was
determined on αSMA and vWF double stained lung sections,
using the 50% αSMA layer circumference as a cutoff at a 400x
magnification by counting 50 blood vessels per lung section
(Alapati et al., 2011; Chen et al., 2011). We excluded fields
with large blood vessels or bronchioli from the analysis. Right
and left ventricular free wall thickness was assessed at a 40x
magnification in a transversal HE-stained section taken halfway
the long axis by averaging 6 measurements per structure. For
each heart RVH was calculated by dividing average RV free wall
thickness and average LV free wall thickness. For morphometric
studies in lung and heart, 6–8 and 10 rat pups per experimental
group were studied, respectively. NIH Image J software was used
for quantitative morphometry. Two independent researchers
blinded to the treatment strategy performed the analysis
(Yi et al., 2004; de Visser et al., 2010; Chen et al., 2016).
Fibrin, IL6, and MCP1 Detection Assays
Extravascular fibrin deposition was quantified in lung tissue
homogenates by Western blotting, using rat fibrin as a standard
by infrared detection (Odyssey infrared imaging system, Licor
Biosciences, Lincoln, NE, USA) as described previously (de
Visser et al., 2009, 2010; Wagenaar et al., 2013). IL6 and MCP1
were quantified in lung homogenates by ELISA, essentially
as recommended by the manufacturer (IL6: RRF600CKX and
MCP1: RRF423CKC, Antigenix America Inc., NY, USA).
Bronchoalveolar Lavages and Protein
Assay
Lung lavages and total protein assay were performed as
previously described (de Visser et al., 2009; Wagenaar et al.,
2013).
Real-Time RT-qPCR
RT-qPCR was performed on a Light Cycler 480 (Roche,
Almere, The Netherlands) at the Leiden Genome Technology
Center (Leiden, The Netherlands), using first-strand cDNA
synthesized from total RNA [SuperScript Choice System (Life
Technologies, Breda, the Netherlands)] and β-actin as a
housekeeping gene reference. RNA was isolated from lung tissue
homogenates (RNA-Bee, Tel-Test Inc, Bio-Connect BV, Huissen,
the Netherlands), as described previously (Wagenaar et al., 2004,
2013). Primers are listed in Table 1.
Cell Culture Experiments
Human pulmonary artery endothelial cells (PAECs; Lonza) were
maintained in EGM-2 with 10% fetal bovine serum (FBS)
and were used for experiments between passages 4 and 8.
The Human microvascular endothelial cell line HMEC-1 was
cultured in MDCB131 (Invitrogen) containing 10% FBS, 10
mM L-glutamine (Sigma), 1 µg/ml hydrocortisone (Sigma),
and 10 ng/ml human epidermal growth factor (Sigma). Both
endothelial cell sources were grown on tissue culture plates
coated with 0.1% gelatin at 37◦C in 5% CO2. Primary bronchial
epithelial cells (PBEC) were obtained from anonymized tumor-
free lung tissue obtained from lung cancer patients at lung
resection surgery by enzymatic digestion as described previously
(van Wetering et al., 2000). Cells were cultured submerged
in a 1:1 mixture of DMEM (Gibco, Grand Island, NY) and
bronchial epithelial growth medium (BEGM; Clonetics, San
Diego, CA) supplemented with 0.4% (w/v) bovine pituitary
extract (BPE), 0.5 ng/ml epidermal growth factor (EGF), 5
µg/ml insulin, 0.1 ng/ml retinoic acid, 10 µg/ml transferrin, 1
µM hydrocortisone, 6.5 ng/ml T3, 0.5 µg/ml epinephrine (all
from Clonetics), 1.5 µg/ml bovine serum albumin (BSA; Sigma),
1 mM HEPES (Gibco), 100 U/ml penicillin, and 100 µg/ml
streptomycin (Bio Whittaker, Walkersville, MD; van Wetering
et al., 2007). Human pulmonary mucoepidermoid carcinoma
cell line NCI-H292 was cultured in RPMI 1640 (Invitrogen)
containing 10% FBS. All cells were grown in a humidified 5%
CO2 water-jacketed incubator at 37
◦C and routinely tested for
absence of mycoplasma contamination. At confluence, cells were
starved overnight (0% FBS or growth factor) and incubated with
recombinant human BMP9 (5 ng/ml; 3209-BP/CF, R&D Systems,
Minneapolis, MN) for 4 h. A dose of 5 ng/ml of BMP9 was
chosen based on effective stimulation of BMP9/ALK1/pSMAD-
dependent signaling with 5 ng/ml of BMP9 in pulmonary
arterial endothelial cells in the context of pulmonary arterial
hypertension (Long et al., 2015) and the culture times in the
presence of BMP9 where chosen based on previous studies on
inflammatory cytokine production by endothelial cells (Nilsen
et al., 1998; Gargalovic et al., 2006). Thereafter, RNA was
extracted and quantitative PCR was used to determine mRNA
expression. Total RNA was isolated with the NucleoSpin RNA
II kit (BIOKE, Leiden, Netherlands) according to the supplier’s
manual. cDNA was synthesized with the RevertAid First Strand
cDNA Synthesis Kit (Thermo Scientific, Leusden, Netherlands).
Real-time quantitative PCR was performed on a CFX connect
real-time PCR system (Bio-Rad, Veenendaal, Netherlands). All
data were analyzed in triplicate using acidic ribosomal protein
(ARP) as a gene reference and the non-stimulated condition was
set to 1. Relative expression levels are presented as mean± SEM.
Primers are listed in Table 1.
Iodinated BMP9 Binding Assay
Iodination of BMP9 was performed according to the chloramine
T method and cells were subsequently affinity labeled with
the radioactive ligand as described before (Scharpfenecker
et al., 2007). Cell lysates were immunoprecipiated with specific
antibodies against ALK1, ALK2, ALK5, Endoglin, and BMPR2.
The generation and characterization of these antibodies have
been previously published (ten Dijke et al., 1994; Yamashita et al.,
1994; Rosenzweig et al., 1995).
Frontiers in Physiology | www.frontiersin.org 4 July 2017 | Volume 8 | Article 486
Chen et al. BMP9 Attenuates Experimental Bronchopulmonary Dysplasia
TABLE 1 | Sequences of oligonucleotides for forward and reverse primers for real-time RT-PCR.
Gene Species Forward primer Reverse primer
ALK1 Rat 5′-CGTGCTGGTCAAGAGCAACTT-3′ 5′-GCTTTGCGAGTGCATCACA-3′
ALK2 Rat 5′-GGAAGTGGCCAGGAGGAT-3′ 5′-GGGTCATTGGGAACAACATC-3′
BMP9 Rat 5′-AAGGGACCAGTTGCCATTC-3′ 5′-CAGACCCATATACCCCAGTCA-3′
BMPRII Rat 5′-CCCCGAGGAGATCATTACAA-3′ 5′-ACGTGCCACCATTCTTTACC-3′
Endoglin Rat 5′-GCTGCGGCATGAAAGTGA-3′ 5′-GGTAAGCCTGATGGCAAATTG-3′
IL6 Rat 5′-ATATGTTCTCAGGGAGATCTTGGAA-3′ 5′-TGCATCATCGCTGTTCATACAA-3′
TMEM100 Rat 5′-TGGTCCTTCTCTCCCAAGTCA-3′ 5′-CAGGGTGGAAGCTCACAAAAA-3′
β-actin Rat 5′-TTCAACACCCCAGCCATGT-3′ 5′-AGTGGTACGACCAGAGGCATACA-3′
ALK1 Human 5′-CTGGTTCCGGGAGACTGAGAT-3′ 5′-TGCGGGAGGTCATGTCTGA-3′
ALK2 Human 5′-TGCCTTCGAATAGTGCTGTC-3′ 5′-CATCAAGCTGATTGGTGCTC-3′
ARP Human 5′-CACCATTGAAATCCTGAGTGATGT-3′ 5′-TGACCAGCCGAAAGGAGAAG-3′
BMPRII Human 5′-AACTGTTGAGCTGATTGGC-3′ 5′-CGGTTTGCAAAGGAAACAC-3′
ID1 Human 5′-CTGCTCTACGACATGAACGG-3′ 5′-GAAGGTCCCTGATGTAGTCGAT-3′
IL6 Human 5′-CCCACACAGACAGCCACTCA-3′ 5′-CCGTCGAGGATGTACCGAAT-3′
MCP1 Human 5′-GCAATCAATGCCCCAGTCA-3′ 5′-GCCTCTGCACTGAGATCTTCCT-3′
TMEM100 Human 5′-TGCTGTGGTTGTCTTCATCG-3′ 5′-CTCTCCCGTCTCTTGGCTTTC-3′
Statistical Analysis
Values are expressed as mean ± SEM. Differences between
experimental groups in the in vivo experiments were analyzed
by one-way ANOVA, followed by Tukey’s multiple comparisons
test. For comparison of survival curves, Kaplan–Meier analysis
followed by a log rank test was performed. Differences between
groups in the in vitro experiments were analyzed by Student
t-test. For statistical analysis the GraphPad Prism version 7
software package was used (San Diego, CA, USA). A p < 0.05
was considered statistically significant.
RESULTS
Expression of Genes Involved in
BMP9-Dependent Signaling
In RA-exposed rat lungs (Figure 1), mRNA expression of
ALK1 (Figure 1B; p < 0.001), Endoglin (Figure 1E; p <
0.001), and TMEM100 (Figure 1F; p < 0.001) increased with
advancing age, whereas mRNA expression of BMP9 (Figure 1A),
ALK2 (Figure 1C), and BMPRII (Figure 1D) did not change
significantly. After exposure to hyperoxia for 10 days, mRNA
expression of BMP9 (p < 0.001), ALK1 (p < 0.001), ALK2 (p <
0.001), and TMEM100 (p< 0.001) was lower and that of BMPRII
(p< 0.05) and Endoglin (p< 0.001) was significantly higher than
in RA controls.
Expression of TMEM100 in Neonatal Lung
On day 10 TMEM100 was expressed in the vessel wall of veins
and arterioles (Figures 2A–C). In arterioles, TMEM100 protein
expression (Figure 2D) had a staining pattern very similar to
elastin (see Figure 7E), showing a double layer, in which the
internal elastic lamina is localized directly under the vWF-
positive endothelial layer (Figures 2E,F). Exposure to hyperoxia
resulted in a decrease in TMEM100 expression in pulmonary
arterioles and veins. In very severe BPD TMEM100 protein levels
were very low and only expressed in the wall of small arterioles
(Figures 2G–I).
Expression of pSMAD1 and pSMAD2 in
Neonatal Lung
On day 10 pSMAD1 (Figures 3A,B,D,E) and pSMAD2
(Figures 3G,H,J,K) were expressed in multiple cell types,
including vascular endothelial cells (Figures 3C,F,I,L), and
showed, as expected, a nuclear staining pattern, because
both activated SMADs are directed toward the nucleus
after binding to SMAD4 (Pardali and Ten Dijke, 2012).
Exposure to hyperoxia had no effect on this staining
pattern.
Effects of BMP9 on Growth and Survival
Body weight after 10 days in RA (Figure 4A) was comparable
in BMP9 and NaCl-treated Wistar rat pups (18 g) and
decreased significantly to 13 g after exposure to hyperoxia
for 10 days (p < 0.001), compared to RA controls. All RA
pups survived (Figure 4B) after treatment with either 0.9%
NaCl or BMP9. Exposure to 100% O2 for 10 days resulted
in a 46% drop in survival (p < 0.05), compared to RA
controls and was not influenced by the administration of BMP9
(Figure 4B).
Effects of BMP9 on Lung Airway
Development, Inflammation, and Collagen
Deposition
Administration of BMP9 during normal neonatal development
for 10 days did not have negative effects on the lung
regarding the number of alveolar crests, mean linear intercept
(MLI), pulmonary vessel density, alveolar septal thickness,
influx of macrophages and neutrophilic granulocytes, and
collagen IIIA expression (Figures 5, 6). Exposure to 100%
O2 for 10 days resulted in a heterogeneous distribution of
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FIGURE 1 | Relative mRNA expression of bone morphogenetic protein 9 (BMP9; A) activin receptor-like kinase 1 (ALK1; B) activin receptor-like kinase 2 (ALK2; C)
BMP type II receptor (BMPRII; D) Endoglin (E) and Transmembrane protein 100 (TMEM100; F) in lung of rat pups on days 1, 3, 6, and 10 after birth and in adult rats
during normal development in RA (white bars) and after exposure to 100% O2 (shaded bars), using β-actin as a house keeping gene reference. Values are expressed
as mean ± SEM (N = 6–10). Differences between groups were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01,
and ***p < 0.001 vs. own age-matched RA controls. 11p < 0.01 and 111p < 0.001 vs. RA control on day 1.
enlarged alveoli, which was demonstrated by a reduced number
of alveolar crests [2.6-fold, p < 0.001; Figures 5C,I (per
field) and Figure 5J (per tissue ratio)] and increased MLI
(1.4-fold, p < 0.001; Figure 5K) compared to RA controls.
These simplified alveoli were surrounded by thick septa (1.8-
fold, p < 0.001; Figures 5C, 6M). In addition, exposure to
hyperoxia reduced the number of blood vessels per tissue
ratio (1.5-fold, p < 0.001; Figure 5L) compared to RA-exposed
controls. Furthermore, neonatal exposure to 100% O2 induced
an inflammatory and fibrotic response, characterized by a
significant pulmonary influx of macrophages (13.5-fold, p <
0.001; Figures 6C,N) and neutrophils (24.8-fold, p < 0.001;
Figures 6G,O), and increased collagen IIIA deposition in thick
alveolar septa (8.9-fold, p < 0.001; Figures 6K,P), compared
to RA controls. Treatment of hyperoxia-induced experimental
BPD with BMP9 for 10 days improved aberrant alveolar
development by increasing the number of alveolar crests [1.4-
fold, p < 0.05; Figures 5D,I (per field) and 1.8-fold, p <
0.01; Figures 5D,J (per tissue ratio)] and reducing MLI (1.1-
fold, p < 0.05; Figure 5K), and decreasing alveolar septal
thickness (1.5-fold, p < 0.001; Figures 5D, 6M). Furthermore,
BMP9 attenuated the hyperoxia-induced inflammatory and
fibrotic response by preventing the influx of macrophages
(3.2-fold, p < 0.01; Figures 6D,N) and neutrophils (4.2-
fold, p < 0.01; Figures 6H,O), and reducing collagen IIIA
expression (1.7-fold, p < 0.01; Figures 6L,P), respectively,
compared to O2-exposed controls. However, beneficial effects
on reduced hyperoxia-induced vascularization (Figure 5L) were
absent.
Effects of BMP9 on Pulmonary Vascular
Remodeling and Right Ventricular
Hypertrophy
BMP9 did not have adverse effects on pulmonary arterial vascular
remodeling (Figures 7B,F,J) and RVH (Figure 7N) during
normal neonatal development (Figures 7A,E,I,M). Exposure
to 100% O2 for 10 days induced vascular remodeling with
increased pulmonary arterial medial wall thickness (2.5-fold, p<
0.001; Figures 8A,B), determined on αSMA-stained (Figure 7C)
and on elastin-stained sections (Figure 7G), and increased
muscularization of small arterioles (1.5-fold, p < 0.001;
Figure 8C), determined on αSMA (brown) and vWF (blue)
double stained sections (Figure 7K), as markers for vascular
remodeling and PAH. In addition, the ratio RV/LV free wall
thickness (1.5-fold, p < 0.05; Figures 7O, 8D) as a marker for
RVH increased after exposure to hyperoxia. Treatment with
BMP9 for 10 days had no beneficial effect on hyperoxia-induced
pulmonary vascular remodeling (Figures 7D,H,L, 8A–C) and
RVH (Figures 7P, 8D).
Effects of BMP9 on Pulmonary Vascular
Leakage, Extravascular Fibrin Deposition,
IL6 and MCP1 Expression, and mRNA
Expression of ALK1, ALK2, TMEM100,
and IL6
To establish the effect of pulmonary edema by capillary-alveolar
leakage we measured total protein concentration in BALF.
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FIGURE 2 | Representative lung sections stained for transmembrane protein 100 (TMEM100; A,D,G), α smooth muscle actin (αSMA; B,E,H), and von Willebrand
Factor (vWF; C,F,I) of rat pups kept in RA (A–F) or 100% O2 (G–I) until 10 days of age. Boxed areas in panels (A–C) are shown as a high power magnification in
panels (D–F), respectively. The boxed areas in panels (G–I) are shown in the inset in the right lower boxed corner as a high power magnification. a, alveolus; Ar,
arteriole; Br, bronchus; v, vein.
Protein concentration on postnatal day 10 was increased 2.1-
fold (p < 0.05) after exposure to 100% O2 compared to
RA controls, but was not affected by BMP9 (Figure 9A).
Extravascular fibrin deposition in lung tissue homogenates was
increased in experimental BPD on neonatal day 10 (10-fold;
p < 0.001; Figure 9B), but administration of BMP9 did not
reduce hyperoxia-induced pulmonary fibrin deposition. IL6
and MCP1 expression in lung tissue homogenates increased
1.4-fold (p < 0.05) for IL6 (Figure 9C) and 2.9-fold (p <
0.05) for MCP1 (Figure 9D) after exposure to 100% O2 for
10 days. Treatment of experimental BPD with BMP9 showed
a tendency toward lower IL6 and MCP1 levels. BMP9 had
no effect on mRNA expression of IL6 (Figure 9E), ALK1
(Figure 9F), ALK2 (Figure 9G), and TMEM100 (Figure 9H)
during normal neonatal development. Exposure to 100% O2 for
10 days increased the expression of IL6 (42-fold; p < 0.001) and
decreased the expression of ALK1 (3-fold; p< 0.001), ALK2 (1.6-
fold; p < 0.001), and TMEM100 (10-fold; p < 0.001). Treatment
with BMP9 for 10 days did not have any effect on the expression
of ALK1, ALK2, and TMEM100, but showed a tendency
toward lower IL6 mRNA levels compared to hyperoxia-exposed
controls.
Binding of BMP9 to Its Receptor Complex
Activates the Intracellular SMAD Pathway
in Endothelial Cells
Next we investigated BMP9 binding to its membrane
receptor complex in human microvascular endothelial
cells (HMEC) after affinity labeling with iodinated BMP9
(Figure 10A) and activation of the intercellular SMAD pathway
by BMP9 in endothelial cells (Figure 10B). Crosslinked
ligand-receptor complexes were immuno-precipitated with
specific antisera against ALK1, ALK2, ALK5, BMPR2, and
Endoglin (Figure 10A). BMP9 predominantly binds to ALK1,
BMPR2, Endoglin and weakly to ALK2, but not to ALK5.
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FIGURE 3 | Representative lung sections stained for pSMAD1 (A,B,D,E), pSMAD2 (G,H,J,K), and von Willebrand Factor (vWF; C,F,I,L) of rat pups kept in RA
(A–C,G–I) or 100% O2 (D–F,J–L) until 10 days of age. The boxed areas in panels (A,D,G,J) are shown as high power magnification in panels (B,E,H,K), respectively.
a, alveolus; Ar, arteriole; Br, bronchus.
BMP9 activation of the intracellular SMAD pathway was
demonstrated by Western blotting in cell lysates of primary
human pulmonary arterial endothelial cells (PAEC) and
HMEC incubated with BMP9 (5 ng/ml) for 4 h. SMAD1
activation was demonstrated with a phosphorylated SMAD1
specific antibody, using GAPDH as a loading control
(Figure 10B).
BMP9 Treatment Suppresses Endothelial
Inflammatory Cytokine Production and
Stimulates TMEM100 Expression In vitro
The reduction of the pulmonary influx of macrophages and
neutrophils, and a trend toward lower IL6 and MCP1 expression
in the lungs of BMP9-treated neonatal rats challenged by
exposure to hyperoxia suggests that BMP9 administration
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FIGURE 4 | Body weight (A) in RA (white bars) and O2-exposed (100% O2 for 10 days; shaded bars) rat pups injected with 0.9% NaCl or BMP9 (2.5 µg kg
−1 twice
daily for 10 days). Data are expressed as mean ± SEM. Differences between groups were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons
test. ***p < 0.001 vs. age-matched 0.9% NaCl treated RA controls. Kaplan-Meier survival curves (B) of BMP9-treated rat pups exposed to 100% O2 (1),
age-matched O2-exposed controls (•) and room air exposed controls treated with BMP9 () or 0.9% NaCl (H) for 10 days after birth. Data are expressed as mean
percentage ± SEM of pups surviving at the observed time point. N =18–24. *p < 0.05 vs. age-matched 0.9% NaCl treated RA controls.
FIGURE 5 | Representative HE-stained lung sections (A–D) and lung sections stained for von Willebrand Factor (vWF; E–H) in rat pups kept in RA (A,B,E,F) or 100%
O2 (C,D,G,H) until 10 days of age. Lung morphometry, including the quantifications of alveolar crests (I,J), mean linear intercept (K) and number of pulmonary
vessels per tissue ratio (L) was determined on paraffin sections in Wistar rats on day 10 kept in RA (open bars) or 100% O2 for 10 days (shaded bars). Pups were
injected daily with 0.9% NaCl or BMP9 (2.5 µg kg−1 twice daily for 10 days). Values are expressed as mean ± SEM. N = 8. Differences between groups were
analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. **p < 0.01 and ***p < 0.001 vs. RA controls. †p < 0.05 and ††p < 0.01 vs.
age-matched O2-exposed controls. Three independent experiments were performed. a, alveolus.
attenuates the pulmonary oxidative stress-induced inflammatory
and fibrotic response. Therefore, we studied the underlying
mechanisms by which BMP9 treatment reduces inflammation
in the hyperoxia-exposed lung by measuring the expression
of important pro-inflammatory cytokines involved in BPD
pathology, including MCP1 and IL6 (Wagenaar et al., 2004;
Bhandari, 2014). First, we analyzed the expression of BMP
receptors and the downstream target gene TMEM100 in
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FIGURE 6 | Representative lung sections stained for the macrophage marker ED1 (A–D), neutrophilic granulocyte marker MPO (E–H), or Collagen III (I–L) in rat pups
kept in room-air (RA; A,B,E,F,I,J) or 100% O2 (C,D,G,H,K, L) until 10 days of age. Quantification of septal thickness (M) the pulmonary influx of macrophages
(N) and neutrophilic granulocytes (O), and collagen III deposition (P) was determined on lung paraffin sections in Wistar rats after exposure to RA (open bars) or 100%
O2 for 10 days (shaded bars). Pups were injected subcutaneously daily with 0.9% NaCl or BMP9 (2.5 µg kg
−1 twice daily for 10 days). Values are expressed as mean
± SEM. N = 8. Differences between groups were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. **p < 0.01 and ***p < 0.001 vs. RA
controls. ††p < 0.01 and †††p < 0.001 vs. age-matched O2-exposed controls. Three independent experiments were performed. a, alveolus.
human primary pulmonary arterial endothelial cells (PAEC),
human microvascular endothelial cell line (HMEC), human
primary bronchial epithelial cells (PBEC), and the human
epithelial pulmonary mucoepidermoid carcinoma cell line NCI-
H292 (Figure 11A) and tested their sensitivity to BMP9, by
examining the expression of ID1, which is a direct target
gene of BMP/SMAD signaling (Figure 11B). Both epithelial
and endothelial cells expressed BMP receptors ALK1, ALK2,
and BMPRII, and TMEM100 (Figure 11A) and responded to
BMP9 with increased expression of ID1 (Figure 11B). However,
epithelial cells showed markedly lower levels of BMPRII, ALK1,
and TMEM100 mRNA, which was accompanied with a lower
response toward BMP9 stimulation in epithelial cells compared
to endothelial cells (Figure 11B). Highest TMEM100 expression
was observed in HMECs (Figure 11A). ALK2 expression was
only reduced in the NCI-H292 cells (Figure 11A). Next we
studied the role of BMP9 on pro-inflammatory cytokine
production and TMEM100 expression in endothelial cells (PAEC
and HMEC). BMP9 treatment for 4 h significantly decreased
MCP1 (Figure 11C) and IL6 (Figure 11D) mRNA levels in
PAEC and HMEC endothelial cells, and increased TMEM100
expression in PAECs only (Figure 11E). The absence of BMP9-
induced expression of TMEM100 in HMECs is probably due to
its very high expression at basal culturing conditions, compared
to PAECs (Figure 11A), thereby preventing additional induction
of its expression by BMP9 in HMECs (Figure 11E).
DISCUSSION
Lung injury induced by chronic exposure to hyperoxia
in neonatal rat pups is a valuable in vivo model for
severe experimental BPD (Wagenaar et al., 2004). BMP9
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FIGURE 7 | Representative lung sections stained for α smooth muscle actin (αSMA, A–D) and elastin (E–H), double-stained for von Willebrand Factor (blue) and
αSMA (brown I–L) and HE stained heart sections (M–P) of rat pups kept in RA (A,B,E,F,I,J,M,N) or 100% O2 (C,D,G,H,K,L,O,P) until 10 days of age. Pups were
injected twice a day with 0.9% NaCl or 2.5 µg kg−1 BMP9. LV, left ventricle; RV, right ventricle.
FIGURE 8 | Medial wall thickness was quantified on αSMA-stained lung sections (A) and elastin stained sections (B), the percent of muscularized blood vessels was
quantified in vWF and αSMA double-stained lung sections (C) and the RV/LV free wall thickness ratio was measured in HE-stained heart tissue sections as a marker
for right ventricular hypertrophy (D) in rat pups kept in RA (open bars) or 100% O2 for 10 days (shaded bars). RA and O2 pups were injected twice a day for 10 days
with 0.9% NaCl or 2.5 µg kg−1 BMP9. Values are expressed as mean ± SEM. N = 8 for medial wall thickness and vascular muscularization and N = 10 for RV/LV
ratio. Differences between groups were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. *p < 0.05 and ***p < 0.001 vs. RA controls.
Three independent experiments were performed. LV, left ventricle; RV, right ventricle.
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FIGURE 9 | Quantification of total protein concentration in bronchoalveolar lavage fluid (BALF; N = 10, A) as a marker for vascular leakage, extravascular fibrin
deposition (N = 8, B), protein expression of IL6 (N = 8, C), and MCP1 (N = 8, D) and relative mRNA expression (N = 8) of IL6 (E), ALK1 (F), ALK2 (G), and TMEM100
(H) in lung tissue homogenates on day 10. RA pups (open bars) and O2 pups (shaded bars) were injected twice a day with 0.9% NaCl or 2.5 µg kg
−1 BMP9 for 10
days. Differences between groups were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. Values are expressed as mean ± SEM. *p <
0.05 and ***p < 0.001 vs. RA controls.
FIGURE 10 | BMP9 binds to endogenous cell surface receptors (A) and activates intracellular SMAD pathway in endothelial cells (B). Human microvascular
endothelial cells (HMECs) were affinity-labeled with iodinated BMP9 and crosslinked ligand-receptor complexes were immuno-precipitated with specific antisera as
indicated (A). BMP9 predominantly binds to ALK1, BMPR2, Endoglin, and weakly to ALK2, but not to ALK5. Input is also shown. Representative Western blots
showing BMP9-induced phosphorylated SMAD1 expression in cell lysates of human primary pulmonary arterial endothelial cells (PAEC) and HMEC that were
incubated with BMP9 (5 ng/ml) or PBS for 4 h. GAPDH was included as a loading control.
treatment of rat pups with experimental BPD attenuated
neonatal chronic lung disease by improving aberrant alveolar
development, demonstrated by reduced alveolar enlargement
and septal thickness, and reducing pulmonary inflammation
and extravascular collagen deposition. BMP9 did not improve
hyperoxia-induced lung aberrant vascularization, pulmonary
vascular remodeling, right ventricular hypertrophy (RVH),
capillary alveolar leakage and fibrin deposition, nor did it
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FIGURE 11 | Relative mRNA expression of BMPRII, ALK1, ALK2, and TMEM100 in human primary pulmonary arterial endothelial cells (PAEC), human microvascular
endothelial cell line (HMEC), human primary bronchial epithelial cells (PBEC), and human epithelial pulmonary mucoepidermoid carcinoma cell line (NCI-H292) (A).
Relative mRNA expression of inhibitor of DNA binding 1 (ID1) in endothelial cells (PAEC and HMEC) and epithelial cells (PBEC and NCI-H292) treated with 5 ng/ml of
BMP9 for 4 h (B). Relative mRNA expression of MCP-1 (C), IL6 (D), and TMEM100 (E) in endothelial cells (PAEC and HMEC) treated with BMP9 for 4 h. Values are
expressed as mean ± SEM. ***p < 0.001 vs. Control using acidic ribosomal protein (ARP) as a reference gene.
have adverse effects on normal neonatal lung development.
The data show that BMP9 may have therapeutic potential to
restore aberrant alveolar development and attenuate pulmonary
inflammation and fibrosis in preterm infants with severe neonatal
chronic lung disease or BPD.
Differential expression of the receptors BMPRII, ALK1, ALK2,
and Endoglin, the ALK1 ligand BMP9 (David et al., 2007)
and the ALK1 downstream gene target TMEM100 (Somekawa
et al., 2012) was observed during normal lung development
and in hyperoxia-induced neonatal lung disease. Assuming that
regulation of gene expression takes place at a transcriptional
level, this suggests a role for BMP9/ALK1/BMPRII-dependent
signaling in the pathogenesis of severe (experimental) BPD,
in which aberrant alveolar and vascular development, vascular
remodeling, and inflammation all play a crucial role. Alejandre-
Alcazar et al. (2007) reported that mice with hyperoxic neonatal
lung injury had higher mRNA expression of TGF-β and BMP
superfamily receptors, including ALK1 and BMPRII, compared
to RA controls. However, we found a decrease in ALK1
mRNA expression and an increase in BMPRII and Endoglin
mRNA expression in lungs of hyperoxia-exposed rat pups. This
discrepancy inmRNA response to hyperoxiamay be explained by
differences in species (mice vs. rats), oxygen concentration (85 vs.
100%) and duration of the hyperoxic period (7/14/21/28 vs. 10
days). The role of BMP9 in experimental neonatal chronic lung
disease is still unclear. The relatively low expression of ALK1 and
TMEM100 in hyperoxia-induced neonatal lung injury suggests
that BMP9/ALK1/BMPRII-dependent signaling is relatively low
in (experimental) BPD. This supports the hypothesis that in
hyperoxia-induced neonatal lung disease the balance between
BMP- and TGF-β-dependent signaling is disturbed (Hilgendorff
et al., 2014) and that restoring this imbalance by either decreasing
TGF-β- and/or increasing BMP-dependent signaling may have
therapeutic potential. This hypothesis is supported by clinical
and experimental data demonstrating that (1) excessive TGF-β-
signaling in premature infants and rodents contributes to the
development and severity of lung injury and (experimental)
BPD (Lecart et al., 2000; Vicencio et al., 2002, 2004; Gauldie
et al., 2003; Alejandre-Alcazar et al., 2007; Morty et al., 2009;
Tatler and Jenkins, 2012), (2) blocking of TGF-β-signaling
reduced lung injury and improved alveolarization in mice
with hyperoxia-induced neonatal lung injury (Nakanishi et al.,
2007; Sakurai et al., 2011) by preventing the TGF-β-induced
downregulation of NO signaling enzymes (Bachiller et al., 2010),
and (3) stimulation with BMP9 improves aberrant alveolar
development and reduces lung inflammation and fibrosis (this
study). Not only does overexpression of TGF-β during early
neonatal lung development contribute to experimental BPD, but
very low levels of TGF-β activity can result in aberrant lung
development with altered cell proliferation, alveolar enlargement,
and emphysematous changes in the lung parenchyma (Colarossi
et al., 2005), which strongly suggests that TGF-β expression needs
to be tightly regulated to preserve normal lung development and
prevent lung disease.
The biological role of TMEM100 in lung development and
disease is still unclear. In embryonic and fetal lung TMEM100
Frontiers in Physiology | www.frontiersin.org 13 July 2017 | Volume 8 | Article 486
Chen et al. BMP9 Attenuates Experimental Bronchopulmonary Dysplasia
expression was present in the endothelium of developing
pulmonary arteries (Moon et al., 2015). The spatial expression
of TMEM100 in the lung could not be confirmed after birth
due to the high level of TMEM100 promoter-induced LacZ
expression and subsequent X-gal staining in whole mount organ
specimens and the absence of proper histological analysis of
pulmonary TMEM100 expression after birth (Moon et al., 2010,
2015). TMEM100 knockout mice die in utero on embryonic day
11.5 and lung pathology was only studied in adult inducible
knockout mice, showing internal hemorrhages and vascular
leakage (Moon et al., 2015). Interestingly, the TMEM100 target
gene microfibrillar-associated protein 4 (MFAP4), a protein
that is associated with elastin fiber formation, showed a
similar pattern of expression in the vasculature of the lung as
TMEM100 in our study (Moon et al., 2015). The importance
of MFAP4 in postnatal lung development and disease was
recently demonstrated in knockout mice, showing spontaneous
alveolar enlargement (Holm et al., 2015), strongly suggesting
that MFAP4 and TMEM100 are involved in lung development
and disease. These data support our findings in experimental
BPD, in which aberrant alveolar development was associated
with low TMEM100 expression at the mRNA level and by
immunohistochemical detection, which is a semi-quantitative
measure for protein expression.
The hallmark in BPD is alveolar enlargement which is caused
by aberrant alveolar and vascular development (Baraldi and
Filippone, 2007). BMP9 attenuated alveolar enlargement and
septal thickness in rat pups with hyperoxia-induced neonatal
lung injury. Since alveolar development is angiogenesis-driven
(Thebaud and Abman, 2007) and pro-angiogenic treatment has
therapeutic potential in (experimental) BPD (Thebaud et al.,
2005; Balasubramaniam et al., 2006; de Visser et al., 2009, 2010),
the beneficial effect on alveolar enlargement may be explained
by BMP9/ALK1-dependent stimulation of angiogenesis, which is
supported by a reduction in tumor growth in mice and patients
by anti-angiogenic therapy with pharmacological blockers of
ALK1 (Cunha et al., 2010; Cunha and Pietras, 2011). However,
anti-angiogenic properties of BMP9 have also been reported and
this effect of BMP9may vary during lung development and in the
adult lung (Long et al., 2015). The absence of a beneficial effect of
BMP9 on reduced vascularization suggests that BMP9 improves
hyperoxia-induced aberrant alveolarization not by angiogenesis,
but by other regulatory mechanisms.
Inflammation plays a pivotal role in the pathophysiology
of BPD, because it may contribute to severe lung injury and
fibrosis, and treatment with anti-inflammatory agents protects
against hyperoxia-induced experimental BPD (Yi et al., 2004;
de Visser et al., 2012). BMP9 protected against experimental
BPD in rats by attenuating inflammation, as shown by a
reduced pulmonary influx of macrophages and neutrophils, less
fibrosis, as demonstrated by a reduced extravascular collagen III
deposition, and reduced septal thickness. A protective role for
BMP9 on lung inflammation in experimental BPDwas confirmed
by our in vitro data. Human endothelial cells expressed the
components of the BMP9-ALK1-BMPR2 receptor complex at
high levels, showing highest affinity of BMP9 for ALK1, BMPR2,
and Endoglin, and after BMP9 stimulation produced high levels
of its target genes ID1, pSMAD1, and TMEM100, thereby
confirming the in vitro data by Somekawa (Somekawa et al.,
2012). BMP9 suppressed the expression of the pro-inflammatory
cytokines IL6 and MCP1, suggesting that our control culturing
conditions already led to a pro-inflammatory response. Epithelial
cells were also sensitive for BMP9, but the expression of ID1 was
much lower, which could be explained by a relatively low level of
expression of ALK1 and BMPRII compared to endothelial cells,
suggesting a more significant role for the endothelium in the
BMP9-dependent suppression of the inflammatory pulmonary
response. A protective role of BMP9 on inflammation is
supported by in vitro and in vivo data showing that BMPRII
deficiency causes (1) endothelial inflammation, mediated by
reactive oxygen species (ROS) and NFκB, and atherosclerosis
(Kim et al., 2013), (2) an exaggerated inflammatory response
in human and mouse pulmonary artery smooth muscle cells
after lipopolysaccharide (LPS) stimulation, which is associated
with increased ROS production (Soon et al., 2015), and (3) LPS-
induced pulmonary hypertension in mice (Soon et al., 2015). In
contrast, a pro-inflammatory role of BMP9 was demonstrated in
vitro in human endothelial cells and in vivo in mice in which
BMP9 primed the endothelium, thereby aggravating the acute
LPS-induced recruitment of leukocytes (Appleby and Mitrofan,
2016). These data are in sharp contrast to our in vivo data in
rats in which BMP9 attenuated the inflammatory response. These
differences may be explained by disparities in the experimental
setup, including differences in the injurious stimulus (LPS vs.
oxidative stress) the duration of the injurious stimulus (acute vs.
chronic), species (mouse vs. rat), developmental stage (adult vs.
neonate), and cell culturing conditions.
We found that 2 × 2.5 µg kg−1 day−1 of BMP9 effectively
improved aberrant alveolar development and prevented the
inflammatory response in experimental BPD. This dose of BMP9
is similar to the dosage that most efficiently attenuates PAH
in monocrotaline and Sügen-hypoxia-induced PAH in adult
rodents (Long et al., 2015). BMP9 did not reduce extravascular
fibrin deposition in rat pups with experimental BPD. This was
supported by the absence of a beneficial effect on vascular leakage,
because extravascular fibrin deposition depends on the leakage of
fibrinogen into the alveolar lumen before it can be converted into
fibrin by thrombin on damaged lung epithelial cells (Wagenaar
et al., 2004).
PAH is a late complication of BPD and associated with
right heart disease. Treatment of experimental BPD with BMP9
did not decrease enhanced arteriolar medial wall thickness and
muscularization of the small pulmonary arterioles, markers for
vascular remodeling and PAH, and RVH in neonatal rat pups.
This is in sharp contrast to adult animal models of PAH in which
BMP9 and pharmacological activation of BMPR2 with FK506
reduces and even reverses monocrotalin and Sügen-hypoxia-
induced PAH and RVH in mice and rats (Spiekerkoetter et al.,
2013; Long et al., 2015). This inconsistency in response of BMP9
toward vascular remodeling in neonatal and adult rodents may
be explained by the differences in the injurious stimulus and
in the onset of lung injury between neonatal and adult rats. In
addition, the adult PAH models are characterized by a reduction
in lung BMPRII expression (Long et al., 2009), whereas we
observed an increase in BMPRII in hyperoxia. Neonatal rats
have immature lungs which grow and develop from the saccular
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to the alveolar stage of development during hyperoxia-induced
injury, whereas in adult rodents lung injury is induced in fully
mature lungs. BPD is a multifactorial disease in which aberrant
alveolarization, inflammation, and vascular remodeling-induced
pulmonary hypertension and RVH play an important role. The
beneficial effects of BMP9 in experimental BPD are associated
with multiple contributing factors and include a major anti-
inflammatory and anti-fibrotic effect by preventing the influx of
macrophages and neutrophils to the lung, and reducing alveolar
enlargement, septal thickness, and collagen III deposition in
thick septa. However, BMP9 does not improve survival and
prevent vascular remodeling-induced PAH and RVH, which
are important late complicating factors of severe (experimental
BPD) causing severe morbidity and mortality. Therefore, double
treatment with an endothelin receptor inhibitor, which is a
potent inhibitor of pulmonary hypertension in the clinic and in
experimental BPD (Wagenaar et al., 2013), may be considered in
addition to BMP9 to improve treatment of severe (experimental)
BPD.
The differential expression of ALK1, ALK2, and TMEM100
in rat pups with experimental BPD was not accompanied by
a significant down regulation of phosphorylated SMAD1 and
SMAD2, and was not affected by BMP9 treatment. These data
suggest that BMP9-ALK1-SMAD1-dependent signaling in the
pulmonary vasculature and/or lung epithelium may at least
in part be mediated via protein kinase activation rather than
via SMAD-dependent BMP9 signaling (Pardali and Ten Dijke,
2012). In addition, our in vitro studies using human endothelial
cells suggest that in the absence of the high affinity receptor ALK1
BMP9-dependent signaling may occur via binding of BMP9 to
ALK2.
Aberrant osteogenesis is a potential adverse effect of BMP9
that may hamper the translation of BMP9 to the clinic (Kang
et al., 2004). However, we did not observe adverse effects in
rat pups treated with BMP9 for 10 days and in adult rats that
were treated for PAH with the same concentration of BMP9
for a period of 3 weeks (Long et al., 2015), demonstrating that
BMP9-induced aberrant osteogenesis in our neonatal and adult
rat models is absent. If negative effects of treatment with BMP9
in human infants are absent, extrapolation of the beneficial
effects of BMP9 treatment in rat pups with experimental
neonatal chronic lung disease to preterm infants with respiratory
failure may result in a novel therapeutic treatment option
for preterm infants with severe BPD by improving aberrant
alveolar development and reducing pulmonary inflammation
and fibrosis, which are major contributors to mortality and
morbidity.
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